699 related articles for article (PubMed ID: 33515918)
1. Potential inhibitors interacting in Neuropilin-1 to develop an adjuvant drug against COVID-19, by molecular docking.
Vique-Sánchez JL
Bioorg Med Chem; 2021 Mar; 33():116040. PubMed ID: 33515918
[TBL] [Abstract][Full Text] [Related]
2. Discovery of natural products to block SARS-CoV-2 S-protein interaction with Neuropilin-1 receptor: A molecular dynamics simulation approach.
Alshawaf E; Hammad MM; Marafie SK; Ali H; Al-Mulla F; Abubaker J; Mohammad A
Microb Pathog; 2022 Sep; 170():105701. PubMed ID: 35963279
[TBL] [Abstract][Full Text] [Related]
3. Computational Screening of Neuropilin-1 Unveils Novel Potential Anti-SARS-CoV-2 Therapeutics.
Afiadenyo M; Adams L; Agoni C; Moane S; Mckeon-Bennett M; Obiri-Yeboah D; Singh J
Chem Biodivers; 2023 Dec; 20(12):e202301227. PubMed ID: 37878727
[TBL] [Abstract][Full Text] [Related]
4.
Eissa IH; Khalifa MM; Elkaeed EB; Hafez EE; Alsfouk AA; Metwaly AM
Molecules; 2021 Oct; 26(20):. PubMed ID: 34684735
[TBL] [Abstract][Full Text] [Related]
5. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
[TBL] [Abstract][Full Text] [Related]
6. Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm.
Verma AK; Aggarwal R
Chem Biol Drug Des; 2021 Apr; 97(4):836-853. PubMed ID: 33289334
[TBL] [Abstract][Full Text] [Related]
7. Abrogation of SARS-CoV-2 interaction with host (NRP1) neuropilin-1 receptor through high-affinity marine natural compounds to curtail the infectivity: A structural-dynamics data.
Humayun F; Khan A; Ahmad S; Yuchen W; Wei G; Nizam-Uddin N; Hussain Z; Khan W; Zaman N; Rizwan M; Waseem M; Wei DQ
Comput Biol Med; 2022 Feb; 141():104714. PubMed ID: 34772509
[TBL] [Abstract][Full Text] [Related]
8. Potential inhibitors of the interaction between ACE2 and SARS-CoV-2 (RBD), to develop a drug.
Benítez-Cardoza CG; Vique-Sánchez JL
Life Sci; 2020 Sep; 256():117970. PubMed ID: 32553928
[TBL] [Abstract][Full Text] [Related]
9. Attacking COVID-19 Progression Using Multi-Drug Therapy for Synergetic Target Engagement.
Coban MA; Morrison J; Maharjan S; Hernandez Medina DH; Li W; Zhang YS; Freeman WD; Radisky ES; Le Roch KG; Weisend CM; Ebihara H; Caulfield TR
Biomolecules; 2021 May; 11(6):. PubMed ID: 34071060
[TBL] [Abstract][Full Text] [Related]
10. Screening, simulation, and optimization design of small molecule inhibitors of the SARS-CoV-2 spike glycoprotein.
Sun C; Zhang J; Wei J; Zheng X; Zhao X; Fang Z; Xu D; Yuan H; Liu Y
PLoS One; 2021; 16(1):e0245975. PubMed ID: 33493227
[TBL] [Abstract][Full Text] [Related]
11. Autophagy, Unfolded Protein Response, and Neuropilin-1 Cross-Talk in SARS-CoV-2 Infection: What Can Be Learned from Other Coronaviruses.
Siri M; Dastghaib S; Zamani M; Rahmani-Kukia N; Geraylow KR; Fakher S; Keshvarzi F; Mehrbod P; Ahmadi M; Mokarram P; Coombs KM; Ghavami S
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206057
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel nonpeptide small-molecule NRP1 antagonists: Virtual screening, molecular simulation and structural modification.
Peng K; Li Y; Bai Y; Jiang T; Sun H; Zhu Q; Xu Y
Bioorg Med Chem; 2020 Jan; 28(1):115183. PubMed ID: 31744780
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
14. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
15. AXL inhibitors selected by molecular docking: Option for reducing SARS-CoV-2 entry into cells.
Galindo-Hernández O; Vique-Sánchez JL
Acta Pharm; 2022 Sep; 72(3):329-343. PubMed ID: 36651539
[TBL] [Abstract][Full Text] [Related]
16. Architecture and hydration of the arginine-binding site of neuropilin-1.
Mota F; Fotinou C; Rana RR; Chan AWE; Yelland T; Arooz MT; O'Leary AP; Hutton J; Frankel P; Zachary I; Selwood D; Djordjevic S
FEBS J; 2018 Apr; 285(7):1290-1304. PubMed ID: 29430837
[TBL] [Abstract][Full Text] [Related]
17. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
18. A transferable deep learning approach to fast screen potential antiviral drugs against SARS-CoV-2.
Wang S; Sun Q; Xu Y; Pei J; Lai L
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34081143
[TBL] [Abstract][Full Text] [Related]
19. Structure-based virtual screening, in silico docking, ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 M
Mohan A; Rendine N; Mohammed MKS; Jeeva A; Ji HF; Talluri VR
Mol Divers; 2022 Jun; 26(3):1645-1661. PubMed ID: 34480682
[TBL] [Abstract][Full Text] [Related]
20. Some Flavolignans as Potent Sars-Cov-2 Inhibitors
Cetin A
Curr Comput Aided Drug Des; 2022; 18(5):337-346. PubMed ID: 35975852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
